Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.

Study Overview

• Status: Completed
• Conditions: Salivary Gland Cancer
• Intervention / Treatment: Drug: Darolutamide; Drug: Goserelin

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Phase 2

Contacts and Locations

Study Locations

• Japan
  • Aichi-ken
    • Nagoya, Aichi-ken, Japan, 466-8560
      • Nagoya University Hospital
  • Chiba
    • Chiba, Chiba, Japan, 260-8677
      • Chiba University Hospital
    • Kashiwa, Chiba, Japan, 277-8577
      • National Cancer Center Hospital East
  • Fukuoka
    • Fukuoka, Fukuoka, Japan, 810-8563
      • National Hospital Organization Kyushu Medical Center
  • Hokkaido
    • Sapporo, Hokkaido, Japan, 060-8648
      • Hokkaido University Hospital
  • Hyōgo
    • Kobe, Hyōgo, Japan, 650-0017
      • Kobe University Hospital
  • Kanagawa
    • Yokohama, Kanagawa, Japan, 236-0004
      • Yokohama City University Hospital
  • Miyagi
    • Sendai, Miyagi, Japan, 980-8574
      • Tohoku University Hospital
  • Osaka
    • Osaka, Osaka, Japan, 541-8567
      • Osaka International Cancer Institute
  • Tokyo
    • Tokyo, Tokyo, Japan, 105-0003
      • The Jikei University Hospital
    • Tokyo, Tokyo, Japan, 113-8519
      • Tokyo Medical and Dental University Hospital
    • Tokyo, Tokyo, Japan, 160-0023
      • Tokyo Medical University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Darolutamide monotherapy group:

1. Signed, written informed consent.
2. Patients older than 20 years.
3. Histologically confirmed any salivary duct carcinoma (SDC), adenocarcinoma (AC)(NOS), or Carcinoma ex pleomorphic adenoma.
4. Patients with locally recurrent(unresectable) or metastatic salivary gland carcinoma who are not applied for surgery or radiation treatment.
5. Presence of measurable or evaluable disease according to RECIST v1.1
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
7. Adequate organ or bone marrow function
8. Patients who agree to practice effective barrier contraception and refrain from sperm donation during the entire study treatment period and 3 months after the last dose of the study drug.

Darolutamide and Goserelin combination therapy group:

1. Signed, written informed consent.
2. Patients older than 20 years.
3. Histologically confirmed as androgen receptor-positive salivary gland carcinoma at the medical institution.
4. Histologically confirmed as salivary gland carcinoma at the medical institution.
5. Patients with locally recurrent(unresectable) or metastatic salivary gland carcinoma who are not applied for surgery or radiation treatment.
6. Presence of measurable or evaluable disease according to RECIST v1.1
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
8. Adequate organ or bone marrow function
9. Patients who agree to practice effective barrier contraception refrain from sperm donation and stop breastfeeding during the entire study treatment period and through 3 months after the last dose of the study drug.

Exclusion Criteria:

Darolutamide monotherapy group:

1. Histologically confirmed as androgen receptor-negative salivary gland carcinoma at a central laboratory.
2. Prior treatment with AR inhibitors, CYP17 enzyme inhibitors, or LH-RH analogue.
3. Metastases in the brain/central nervous system (CNS).
4. Patients who are pregnant or breastfeeding.
5. Synchronous or metachronous malignancies.
6. Participant has a known history of HIV infection.

7. A positive test result for any of the followings:

   • HBsAg positive
   • HBsAb positive and hepatitis B virus (HBV)-DNA positive
   • HBcAb positive and HBV-DNA positive
8. Severe or uncontrolled concurrent heart disease or hypertension.
9. Inability to swallow oral medications.

Darolutamide and Goserelin combination therapy group:

1. Prior treatment with AR inhibitors, CYP17 enzyme inhibitors, LH-RH analogue, Sex Hormones, or Gonadotropin
2. Prior treatment with Darolutamide or Goserelin.
3. Metastases in the brain/CNS.
4. Patients who are pregnant or breastfeeding.
5. Synchronous or metachronous malignancies.
6. Participant has a known history of HIV infection.

7. A positive test result for any of the followings:

   • HBsAg positive
   • HBsAb positive and HBV-DNA positive
   • HBcAb positive and HBV-DNA positive
8. Severe or uncontrolled concurrent heart disease or hypertension.
9. Inability to administer Darolutamide or Goserelin.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Darolutamide monotherapy; Targeted patients: 24	Drug: Darolutamide; Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
Experimental: Darolutamide plus Goserelin; Targeted patients: 32	Drug: Darolutamide; Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.; Drug: Goserelin; Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Darolutamide monotherapy group: Objective response rate(ORR) assessed by investigators	The proportion of patients with confirmed tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by investigators	Up to 13 month
Darolutamide and Goserelin combination therapy group: Objective response rate(ORR) assessed by an Independent Review Committee	The proportion of patients with confirmed tumor response of CR or PR per RECIST 1.1, as assessed by an independent review committee	Up to 13 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Response (DOR)	DOR will be defined among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first.	Up to 13 month
Best Overall Response (BOR)	BOR will be defined as the best response recorded from the start of protocol treatment based on RECIST version 1.1	Up to 13 month
Disease Control Rate (DCR)	DCR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or SD for at least 6 weeks based on RECIST version 1.1.	Up to 13 month
Clinical Benefit Rate (CBR)	CBR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or stable disease (SD) for at least 24 weeks based on RECIST version 1.1.	Up to 13 month
Clinical Benefit Duration (CBD)	CBD will be defined the period starting from the date of enrollment (start of treatment) and ending on the earlier of the date of determination of progression, the date of death from any cause, or the end of the study period.	Up to 13 month
Progression-Free Survival (PFS)	PFS will be defined as the time from the date of the initial dose of study intervention to the date of first documented disease progression as defined in the RECIST version 1.1, or death due to any cause, whichever occurred first.	Up to 13 month
Overall Survival (OS)	OS will be defined as the time from the date of the initial dose of study intervention to the date of the participant's death	Up to 13 month
Adverse events	All adverse events, adverse events with undeniable causal relationship to the investigational drug, severe adverse events (SAEs) and SAEs with undeniable causal relationship to the investigational drug will be evaluated based on CTCAE version 5.0	Up to 30 days after the last dose
Darolutamide monotherapy group: ORR assessed by an Independent Review Committee	The proportion of patients with confirmed tumor response of CR or PR per RECIST 1.1, as assessed by an independent review committee	Up to 13 month
Darolutamide and Goserelin combination therapy group: ORR assessed by investigators	The proportion of patients with confirmed tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by investigators	Up to 13 month
Comparison of androgen receptor (AR) test results in Darolutamide and Goserelin combination therapy group	Comparison of AR test results between each institutional and a central assessment	Baseline
Positivity of Ki-67 in Darolutamide and Goserelin combination therapy group	The proportion of patients who have high expression of Ki-67 by a central assessment	Baseline
Quality of Life assessed using the EuroQol-5Dimention-5Level (EQ-5D-5L) questionnaire	Changes from baseline to each time point in health-related quality of life will be measured using the European Quality of Life Five Dimension Five Level Scale Assessment Questionnaire (EQ-5D-5L). The EQ-5D-5L consists of a description and a health assessment. The health description consists of five dimensions (mobility, self-care, normal activities, pain / discomfort, and anxiety / depression), with each dimension identifying five levels of severity [best (1) - worst (5)]. Health assessment is assessed using a visual analogue scale (VAS)([worse (0) - better (100)].	Up to 30 days after the last dose

Collaborators and Investigators

• Sponsor: National Cancer Center Hospital East
• Collaborators: Bayer Yakuhin, Ltd.
• Investigators: Study Director: Makoto Tahara, MD, PhD, National Cancer Center Hospital East; Study Chair: Naomi Kiyota, MD, PhD, Kobe University Hospital; Study Chair: Susumu Okano, MD, PhD, National Cancer Center Hospital East

Study record dates

Study Major Dates

• Study Start (Actual): April 17, 2020
• Primary Completion (Actual): August 9, 2024
• Study Completion (Actual): March 23, 2026

Study Registration Dates

• First Submitted: January 12, 2023
• First Submitted That Met QC Criteria: January 12, 2023
• First Posted (Actual): January 23, 2023

Study Record Updates

• Last Update Posted (Actual): April 8, 2026
• Last Update Submitted That Met QC Criteria: April 6, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Darolutamide; Androgen receptor (AR)-positive; Salivary gland carcinoma; luteinizing hormone-releasing hormone (LH-RH) analogue
• Additional Relevant MeSH Terms: Mouth Diseases; Stomatognathic Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Site; Neoplasms; Neuromuscular Diseases; Genetic Diseases, Inborn; Head and Neck Neoplasms; Neurodegenerative Diseases; Heredodegenerative Disorders, Nervous System; Salivary Gland Diseases; Genetic Diseases, X-Linked; Spinal Cord Diseases; Motor Neuron Disease; Muscular Atrophy, Spinal; Mouth Neoplasms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Bulbo-Spinal Atrophy, X-Linked; Salivary Gland Neoplasms; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins; Gonadotropin-Releasing Hormone; Goserelin; darolutamide
• Other Study ID Numbers: YCU19003; jRCT2031190241 (Registry Identifier: Japan Registry of Clinical Trials)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No